Barrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target

Benzinga Newsdesk www.benzinga.com Positive 93.0%

Neg 0% Neu 0% Pos 93%

Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Market Perform to Outperform and announces $5.5 price target.